Neuro Central hosted a free online webinar, ‘Drugs and Driving: Discussing the cognitive effects of drugs on driving performance’, featuring…
This Editorial explores the potential use of biomarkers such as TGF-β, neurofilament light polypeptide, autotaxin, α-syn and complement for AD diagnosis.
October babies are more likely to develop the syndrome, according to a study presented at the Congress of the European Academy of Neurology (Amsterdam, The Netherlands).
Researchers hope to distinguish “hype from fact” in long-term cognitive enhancement.
The new retrospective population-based cohort study from the Mayo Clinic included data from 1993 patients with polyneuropathy.
Research suggests increasing synaptic activity could alleviate SMA symptoms: motor function of mice was improved when treated with a glutamate receptor stimulant.
In this edition of our new column, #NCintroduces, Tom Naughton (UCL Cancer Institute) introduces the complex world of chronobiology and circadian rhythms.
Dr Deer discusses his career highlights, most memorable patient cases, and looks ahead at future challenges and trends in the field of neuromodulation.
A scientific communication that attempts to understand the attitudes of Chinese medical students toward clinical neuroscience to provide a necessary step in curriculum development and reform in the neurosciences.
Live event: Wednesday 14th June 2017 07:00 [PDT] 10:00 [EDT] 15:00 [GMT]
Assessing how drugs affect the CNS is becoming an increasing concern, particularly for road safety. In January 2015, the FDA issued the Draft Guidance – Evaluating Drug Effects on the Ability to Operate a Motor Vehicle. 2 years later, where are we now?